One of the protective actions of angiotensin converting enzyme-2 (ACE2) is the inactivation of angiotensin II. Expression and activity of ACE2 was reduced in glomeruli of diabetic patients and in animal models of diabetes. Recently the potential role of recombinant ACE2 administration in preventing diabetic nephropathy (DN) has been shown. Here we have tested the effects of the ACE2 activator, diminazene aceturate (DIZE), in a model of DN.
Introduction
Diabetic nephropathy (DN) is one of the most common causes of the development of end-stage renal disease globally (Giacco et al., 2014) . The pathogenesis of DN is mainly due to uncontrolled or chronic hyperglycaemia (TA, 2014) . DN is characterized pathologically by glomerular hypertrophy, thickening of the basement membrane, apoptosis and fibrosis due to accumulation of extracellular matrix proteins such as collagen and fibronectin (Deshpande et al., 2013) . Proteinuria, albuminuria and glomerular hyperfiltration rate are the clinical features of DN (Gross et al., 2005) .
Activation of the renal renin-angiotensin system (RAS) plays an important role in the progression of DN through generation of the peptide angiotensin II (Ang II) and, consequently, blockade of the RAS protected against the development of diabetic kidney injury (Burns, 2000) . Ang II acts through two angiotensin receptors, AT 1 and AT 2 receptors. In the kidney, Ang II mediates its pathological actions through AT 1 receptors and these actions include cellular differentiation, proliferation, hypertrophy, fibrosis, renal vasoconstriction and increased tubular sodium reabsorption (Ruggenenti et al., 2010) , whereas the functional role of the AT 2 receptors in the development of DN is not completely understood. Recent reports suggest that some actions, such as the anti-inflammatory, antifibrotic, vasodilatory, anti-hypertrophic and anti-apoptotic effects are due to activation of AT 2 receptors (Cha et al., 2013; Ocaranza et al., 2014; Pandey and Gaikwad, 2017) . Although chronic treatments with angiotensin receptor antagonists and ACE inhibitors are effective in retarding the progression of DN, such treatments are not a cure (Bilous et al., 2009; Mauer et al., 2009) , indicating requirement for identifying additional pathways within the RAS system as potential drug targets.
A newly recognized component of the RAS is the enzyme ACE2, which shares 42% homology with ACE but with different biochemical activities. ACE and ACE2 are co-expressed in many tissues and the effects of ACE2 activity are usually opposed to those of ACE. In the kidney, ACE2 activity is reno-protective by cleaving and thus inactivating Ang II and, at the same time, generating the protective peptide angiotensin-(1-7) (Ang 1-7) (Tikellis and Thomas, 2012) . In several animal models of diabetes, ACE2 expression and activity was decreased in renal tissue Leehey et al., 2008) . In male Akita mice, a model of type 1 diabetes, treatment with human recombinant ACE2 reduced albuminuria, mild hypertension, plasma Ang II levels, activation of NADPH oxidase, glomerular hypertrophy and mesangial matrix expansion, thereby preventing the progression of DN (Oudit et al., 2010) . In another study, injection of adenoviral-ACE2 in streptozotocin (STZ)-induced diabetic rats for 4 weeks improved the signs of DN (Liu et al., 2011) . In addition, in patients with type 2 diabetes, expression of glomerular and tubular ACE2 were also reduced (Mizuiri et al., 2008) . Taken together, these studies suggest that ACE2 plays a protective role against the development of DN.
In a range of disease models, the ACE2 activator, diminazene aceturate (DIZE), plays a protective role. Thus, short-term treatment with DIZE prevented the reduction in ACE2 activity in rats with subtotal nephrectomy (Velkoska et al., 2015) . In rats, treatment with DIZE improved the myocardial infarction through inhibiting cardiac inflammation and apoptosis (Qi et al., 2013) . In another study, DIZE prevented hypoxia-induced death of cardiomyocytes through inhibiting high-mobility group box 1 protein (Qi et al., 2016) . There is also evidence that DIZE is beneficial in several diabetes-induced pathologies. Chronic treatment with DIZE prevented the oxidative stress and endothelial damage in db/db mice by increasing ACE2 activity and Ang 1-7 levels (Zhang et al., 2015b) . DIZE also prevented diabetes-induced cardiac electrical changes in STZ-induced diabetic rats (Coutinho et al., 2014) . However, so far little is known about the effects of DIZE on the molecular mechanisms involved in the progression of DN.
Methods

Animal studies and drug treatment
All animal care and experimental procedures were approved by the Institutional Animal Ethics Committee, Birla Institute of Technology and Science, Pilani (BITS Pilani) under Protocol No: IAEC/RES/18/05. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Male adult Wistar rats (180-220 g) were supplied by the central animal facility of BITS Pilani. Animals were maintained under standard environmental conditions and provided with food and water ad libitum.
The study was performed according to the protocol for Type 1 diabetes, as described previously (Goru et al., 2016) . Briefly, diabetes was induced by injecting a single dose of STZ (55 mg·kg À1 , i.p.), dissolved in ice-cold sodium citrate buffer (0.01 M, pH 4.4) and the normal animals were injected only with ice-cold sodium citrate buffer. Animals with plasma glucose (PGL) levels >16 mmol·L À1 after induction of diabetes were included in the study as diabetic animals. All the diabetic animals received an i.p. injection of insulin (2-3 U) every 3 days to maintain blood glucose levels between 16 and 25 mmol·L À1 in order to prevent mortality induced by excessively high blood glucose levels. At 4 weeks after the injection so STZ or saline, renal functional parameters were estimated in all the animals before separation in to experimental groups (8 rats per group). Normal animals (injected with saline) were divided into normal control (NC), NC treated with high dose of DIZE (NC + HD) and diabetic animals ( STZ-treated) grouped into diabetic control (DC), DC treated with low dose of DIZE (DC + LD), DC treated with high dose of DIZE (DC + HD) and DC treated with high dose DIZE and PD123319 (DC + HD + PD). The low dose (5 mg·kg À1 ·day À1 ) and the high dose (15 mg·kg À1 ·day À1 ) of DIZE were administered as single daily i.p. injections (Dhawale et al., 2016) for 4 weeks; PD123319 (10 mg·kg À1 ·day À1 ) was administered as single daily s.c. injections for the last 2 weeks (Pandey et al., 2015) as an addition to the treatment with DIZE. At the end of 8 weeks, kidneys from all the individual groups were processed separately for protein isolation, RNA extraction and for immunohistochemical studies.
Assessment of biochemical parameters in plasma
Biochemical estimations were performed as described by Goru et al. (2016) . Venous blood (0.5mL) was taken at the time of group allocation (4weeks after STZ)and then again at the end of the whole experiment (8 weeks after STZ). All animals were fasted overnight before blood collection. Heparin (200 IU mL -1 of blood) was used as an anticoagulant. The plasma was separated from the blood by centrifuging the blood samples at 2000 x g for 15 min, at 4 o C. Plasma samples were analysed for glucose (PGL), BUN, albumin (PAL) and creatinine (PCr) by using commercially available kits (Accurex).
Immunohistochemistry
Immunohistochemistry was performed as described previously (Pandey et al., 2015) . Briefly, kidney sections (5 μm) were taken from paraffin blocks and deparaffinized with xylene, followed by antigen retrieval by heating in citrate buffer (10 mmol·L À1 , and anti-rabbit and anti-goat HRP-conjugated secondary antibody was used, followed by detection with diaminobenzidine (DAB) as a chromogen. The slides were counterstained with haematoxylin, dehydrated with alcohol and xylene and mounted in DPX (Sigma-Aldrich). At least 25 kidney sections from each group were observed, and images were captured at 100× magnification by using Olympus microscope (model no. BX51, Olympus, Tokyo, Japan). All the images were analysed using ImageJ software (NIH, Bethesda, MD, USA) for calculating DAB-positive area.
Glomeruli isolation from whole kidney
Kidneys from both normal and diabetic animals were collected and placed in ice-cold PBS, pH 7.4, and glomeruli were isolated as described previously (Goru et al., 2016) . Briefly, kidneys were cut into thin slices, the medullary portion was removed carefully and the cortical area was minced with a scalpel blade to a paste-like consistency. This was passed through a stainless steel sieve with a pore size of 250 μm. The material that passed through this sieve was suspended in ice-cold PBS and passed through three consecutive cell strainers (200, 100 and 70 μm), pluriStrainer set 3 (pluriSelect, Leipzig, Germany). The glomeruli retained on the 100 and 70 μm cell strainers were washed with ice-cold PBS and resuspended in ice-cold PBS. These glomeruli were assessed under a light microscope and used for Western blotting analysis.
Protein isolation and Western blotting
Western blotting was carried out as described previously (Goru et al., 2016) . Immunoblotting was performed by using rabbit monoclonal antibodies against: TGF-β, cleaved caspase-3, cleaved PARP, Smurf2 (Cell Signaling Technology), ACE2 and AT 2 receptors (Santa Cruz Biotechnology).
All antibodies were used in 1:1000 (v/v) dilutions. As secondary, anti-rabbit IgG, HRP-linked antibody, was used in 1:20 000 (v/v) dilution. Proteins were detected by using the ECL system and Hyperfilm. Immunoblots were quantified by densitometric analysis using ImageJ software, and the exposures were in the linear dynamic range; TGF-β, cleaved caspase-3, cleaved PARP, ACE2 and AT 2 receptor proteins were normalized using β-actin.
Estimation of systemic and tissue-specific levels of ACE, ACE2, Ang II and Ang 1-7
Plasma, urine, whole kidney and isolated glomeruli samples were obtained from rats (n = 6 per group) of all the groups. Levels of ACE, ACE2, Ang II and Ang 1-7 were assayed with ELISA kits following the manufacturer's recommendations (Wuhan Fine Biological Technology Co., Ltd., Wuhan, China) (Zhang et al., 2015a) .
RNA isolation and real-time polymerase chain reaction (RT-PCR)
RNA isolation and RT-PCR were performed as described previously (Goru et al., 2016) . Briefly, RNA was reverse transcribed, and RT-PCR was performed using the FastStart Essential DNA Green MAS1ter (Roche, Penzberg, Germany). Relative expression of each gene of interest was evaluated on LightCycler® 96 Real-Time PCR System (Roche) using LightCycler Software (Roche). Abundance of targeted mRNA was normalized against 18 s mRNA. All the primers used in the study are listed in Table S1 .
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Data are presented as mean ± SEM, and n refers to number of animals in a particular group. Statistical analysis was performed using GraphPad Prism, version 5.01 (GraphPad Software Inc., La Jolla, CA, USA). Statistical significance was determined with the one-way ANOVA followed by the Tukey's test for multiple comparisons when F achieved P < 0.05. Results were considered significant if P < 0.05.
Materials
STZ and DIZE were obtained from Sigma. Glucose (glucose oxidase-peroxidase), blood urea nitrogen (BUN), creatinine and albumin kits were purchased from Accurex (Mumbai, India). All the other chemicals were purchased from Sigma, unless otherwise mentioned.
Results
Changes in body weight, kidney weight and kidney weight/body weight ratio by treatment with diminazene aceturate (DIZE) and DIZE in presence of the AT 2 receptor antagonist PD123319
STZ-induced diabetic animals showed significantly decreased body weight and increased kidney weight, leading to an increase in the kidney /body weight ratio (Table 1) . This ratio is a marker for the development of DN. Treatment of diabetic rats with the higher dose of DIZE (15 mg·kg À1 ) reversed the increases in kidney weight and decreased the kidney /body weight ratio (Table 1) . However, adding the AT 2 receptor antagonist PD123319 for the last two weeks reversed these effects of DIZE (Table 1) . Further, treatment of normal rats with the high dose of DIZE did not alter theses parameters ( Table 1) .
Effect of DIZE on plasma biochemical parameters in diabetic rats
After 8 weeks, levels of plasma glucose in diabetic rats were significantly higher than in the NC. Treatment with DIZE did not show any significant effects on plasma glucose levels in NC and in diabetes-induced rats (Table 2) . Increased PCr and BUN levels are the indicators of the development of DN in rats. DIZE at both doses (5 and 15 mg·kg À1 ) decreased the increased PCr and BUN levels in diabetic rats. These effects were not dose-dependent (Table 2) . When compared with control animals, PAL levels were significantly decreased in diabetic control rats and this decrease was significantly inhibited by both doses of DIZE, again without dose-dependence (Table 2 ). This normalisation of these biochemical parameters by DIZE suggests that DIZE protects against renal damage in diabetic animals. However, DIZE treatment in the presence of PD123319 failed to normalize the diabetes-induced changes in plasma (Table 2) . In normal rats, DIZE did not alter any of the plasma biochemical parameters measured (Table 2 ).
ACE2 activation prevented renal fibrosis and apoptosis
Renal fibrosis and apoptosis are considered to be the underlying causes for the development of diabetic kidney disease. In this study, we found increased expression of the profibrotic marker, TGF-β, and increased markers of apoptosis such as Table 1 Effect of DIZE alone or with the AT 2 receptor antagonist PD123319, on morphometric parameters Values shown are means ± SEM; n = 8 rats per group. a P < 0.05, significantly different from NC and NC + HD. b P < 0.05 , significantly different from DC. c P < 0.05, significantly different from DC + HD. Table 2 Effect of DIZE alone or with PD123319 on plasma biochemical parameters
NC 6 ± 0.5 132 ± 7.6 7.7 ± 0.9 42 ± 1 NC + HD 7 ± 0.5 134 ± 5. DIZE treatment increased glomerular ACE2, and AT 2 receptor expression decreased the expression of cleaved PARP and Smurf2
Further, to check the molecular changes in glomeruli, we performed Western blotting experiments on isolated glomeruli. In glomeruli from diabetic animals, expression of ACE2 protein was reduced and this was restored, dose-dependently, by DIZE treatment (Figure 1E, F) . The protein expression of cleaved PARP and Smurf2 was also increased in diabetic glomeruli, and this was reversed by the higher dose of DIZE ( Figure 1E , G, H). Smurf2 is an ubiquitin E3 ligase that degrades SMAD7, a negative regulator of TGF-β, and is the key molecule involved in the development of fibrosis. We also observed increased expression of AT 2 receptor protein in diabetic glomeruli, which was further increased dosedependently by DIZE administration ( Figure 1E, I ).
Effect of treatment with DIZE alone and in presence of PD123319 on systemic and tissuespecific changes in RAS components (ACE, ACE2, Ang II and Ang 1-7)
Changes in the RAS are critical features of the pathogenesis of diabetes. In this study, we measured the systemic (plasma and urinary) levels of major RAS components including ACE and ACE2 and also in whole kidney and in isolated glomeruli (Figure 2) . In diabetic animals, expression of ACE was increased in plasma, whole kidneys and isolated glomeruli ( Figure 2A , C, D), and DIZE treatment reduced ACE in plasma ( Figure 2A ) but not in whole kidney and isolated glomeruli. The AT 2 receptor antagonist, PD123319, combined with DIZE further increased these levels in whole kidney and isolated glomeruli ( Figure 2C, D) . Levels of ACE protein in urine were normal in diabetic animals, and in diabetic animals treated with DIZE. However in diabetic rats treated with DIZE and PD123319, urinary ACE protein was increased ( Figure 2B ). For ACE2, levels in plasma were the same in all experimental groups ( Figure 2E ), whereas in urine, ACE2 levels were increased in diabetic animals, and these levels were normalized by treatment with DIZE alone and again increased when DIZE was combined with PD123319 ( Figure 2F ). In whole kidney, levels of ACE2 protein were elevated in diabetic animals, remained high after DIZE alone and were further increased by treatment with DIZE and PD123319 ( Figure 2G ). In isolated glomeruli, levels of ACE2 protein were lower in diabetic kidneys and this low level was restored after DIZE alone. Adding the AT 2 receptor antagonist to DIZE reversed the effect of DIZE and reduced the protein levels of ACE2 ( Figure 2H ). We also assayed levels of Ang II and Ang 1-7 levels in plasma, whole kidney and isolated glomeruli. Ang II is formed from Ang I through the enzymic actions of ACE and ACE2 acts on Ang II to generate the reno-protective peptide Ang 1-7. In our study, levels of Ang II in plasma, whole kidney and isolated glomeruli were increased by diabetes and this increase was reversed after treatment with DIZE alone. 
BJP S K Goru et al.
Adding PD123319 to DIZE had no effect on this reversal in plasma and whole kidney ( Figure 3A , B), whereas in isolated glomeruli, the AT 2 receptor antagonist again increased the levels of Ang II ( Figure 3C ). For Ang 1-7, levels in plasma, whole kidney and in isolated glomeruli were decreased by diabetes and DIZE treatment improved these levels. Adding PD123319 to DIZE did not alter plasma levels of Ang 1-7 but did reverse the effects of DIZE on levels of Ang 1-7 in whole kidney and isolated glomeruli ( Figure 3D-F) . Importantly, in normal rats, DIZE did not affect any of the components of the RAS measured (Figures 2 and 3) .
Changes in the expression of mRNA for ACE, ACE2, AT 1 , AT 2 and MAS1 receptors, in whole kidney and glomeruli, after treatment with DIZE alone and with PD123319
To determine the effect of our experimental conditions on the transcription of genes for ACE, ACE2, AT 1 , AT 2 and MAS1 receptors, we quantified expression of their mRNA, in whole kidney and isolated glomeruli. In whole kidney, mRNA for ACE was increased in diabetic animals, DIZE treatment normalized this increase and the AT 2 receptor antagonist PD123319 reversed the effect of DIZE ( Figure 4A ). However, for ACE2, gene expression was reduced in whole kidneys from diabetic rats and DIZE treatment increased these levels. This effect of DIZE was not affected by adding the AT 2 receptor antagonist ( Figure 4G ). The mRNA for AT 1 receptors was increased in whole kidneys from diabetic animals, DIZE alone had no effect on this increase but adding PD123319 further elevated these levels ( Figure 4C ). For AT 2 receptors, mRNA expression was increased in whole kidneys by diabetes, DIZE alone further increased these levels which wer not changed by adding PD123319 ( Figure 4D) . Surprisingly, the mRNA for MAS1 receptors was significantly reduced in whole kidneys of diabetic rats and treatment with DIZE alone or combined with PD123319 did not affect this reduction ( Figure 4E ). In isolated glomeruli, expression of these mRNAs showed a pattern similar to that in whole kidney ( Figure 4F -J). Note that DIZE did not affect expression of these genes in normal rats (Figure 4 ).
Expression of AT 1 , AT 2 and MAS1 receptor protein in whole kidney after treatment with DIZE alone and combined with PD123319
Next, we used immunohistochemistry to monitor the expression of AT 1 , AT 2 and MAS1 receptor protein, in our experimental groups. Expression of AT 1 receptor protein was increased in diabetic kidney, DIZE alone significantly normalized this change and combining DIZE and PD123319 reversed the effects of DIZE ( Figure 5A , B). For AT 2 receptors, expression in diabetic kidney was up-regulated and DIZE treatment further increased this expression. This effect of DIZE was blocked by adding PD123319, returning expression of AT 2 receptor protein to the same level as that of diabetic control rats ( Figure 5C, D) . Interestingly, we found down-regulation of MAS1 receptors in diabetic kidney. However, administration of DIZE alone or in presence of PD123319 had no effect on MAS1 receptor expression in diabetic kidneys ( Figure 5E , F).
Figure 2
Systemic and tissue-specific protein expression of RAS components in plasma, urine, whole kidney and isolated glomeruli. (A-D) Levels of ACE protein in plasma, urine, whole kidney and glomeruli; (E-H) Levels of ACE2 protein in plasma, urine, whole kidney and glomeruli. Values shown are means ± SEM. n = 6; *P < 0.05, significantly different from NC and NC + HD, @ P < 0.05, significantly different from DC. $ P < 0.05, significantly different from DC + HD; ns, not significant.
AT 2 receptor blockade re-induced renal fibrosis and apoptosis and prevented the protective actions of DIZE Further, to assess the effects of AT 2 receptor blockade with PD123319 on reno-protection mediated by DIZE, we quantified expression of three markers of fibrosis -TGF-β, fibronectin and collagen IV-along with two markers of apoptosis -cleaved PARP and cleaved caspase-3 -in our experimental groups. We observed increased expression of TGF-β, fibronectin and collagen IV in diabetic kidneys, compared with kidneys from normal rats. Treatment of diabetic rats with DIZE significantly attenuated this increased expression of fibrotic markers and adding PD123319 to DIZE, reversed the DIZE-mediated attenuation ( Figure 6A-F) . We measured the markers of apoptosis in isolated glomeruli and found cleaved PARP and cleaved caspase-3 were increased by diabetes and this increase was normalized by administering DIZE alone. However, DIZE combined with PD123319 was no longer able to reduce these apoptotic markers, and expression of cleaved PARP and cleaved caspase-3 was again markedly increased ( Figure 7A -C).
Discussion
To study the effect of ACE2 activation on the progression of DN, we have used a well-known off-target (Gjymishka et al., 2010) ACE2 activator, DIZE (Kulemina and Ostrov, 2011) . In our study, DIZE treatment significantly improved the renal morphometric parameters -kidney weight and kidney weight/body weight ratio -at higher doses but it did not affect the reduced body weights in diabetic animals ( Table 1) . DIZE treatment also normalized plasma biochemistry -BUN, PCr and PAL -in diabetic animals (Table 2 ). Further, at molecular level, DIZE treatment significantly reduced the expression of fibrotic markers such as TGF-β in whole kidney and Smurf2 in isolated glomeruli, at the higher dose (15 mg·kg À1 ·day À1 ) (Figure 1) . Similarly, DIZE also prevented diabetes-induced renal apoptosis through reducing the expression of cleaved PARP and cleaved caspase-3 in whole kidney, as well as in glomeruli (Figure 1 ). Moreover, in isolated glomeruli from diabetic animals, we observed decreased expression of ACE2 and increased expression of AT 2 receptors, and DIZE treatment restored the low ACE2 levels and further increased expression of AT 2 receptors, dose dependently ( Figure 1 ). These results led us to a conclusion that reno-protection of DIZE involves increased expression of ACE2 and AT 2 receptors. Our results contrast with recent studies of direct ACE2 activation and expression by DIZE. Recently, Haber et al. (2014) demonstrated that DIZE did not activate ACE2 either in in vitro or in ex vivo experiments. Similarly, Raffai et al. (2014) also failed to show ACE2 activation by DIZE in an ex vivo experiment using porcine coronary artery ACE2 activation prevents diabetic nephropathy BJP rings. However, these studies were designed to study the acute effects of DIZE and did not assess the effects of chronic administration of DIZE on ACE2 activation in models in vivo. For instance, Zhang et al. (2015b) reported that chronic treatment with DIZE prevented oxidative stress and endothelial damage in db/db mice by increasing ACE2 activity and Ang 1-7 levels. Moreover, Ali et al. (2013) demonstrated that chronic AT 2 receptor activation induced increased ACE2 activity and reduced BP in Zucker obese rats. In the same study, AT 2 receptor agonists significantly increased the ACE2 activity in HK-2 cells in vitro, and this effect was blocked by a AT 2 receptor antagonist. These reports raised the possibility that DIZE-mediated renoprotection in our study might not be through increased ACE2 expression but through an AT 2 receptor-mediated pathway. To test this, we treated diabetic animals with a high dose of DIZE, with and without the AT 2 receptor antagonist PD123319. Further, to check the effects of chronic treatment with DIZE on several components of the RAS, we have quantified the tissue-specific levels of ACE and ACE2. Although there are several reports on tissue-specific expression of ACE and ACE2 in diabetic kidney, these findings are still a matter of debate. Ye et al. (2006) demonstrated reduced tubular ACE and increased glomerular ACE in 8-week-old female db/db mice. In the same study, they observed increased levels of ACE2 in renal tubules and decreased glomerular ACE2 in diabetic mice. In another study, the same group showed reduced mRNA levels, protein levels and activity of ACE and increased 
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ACE2 protein levels and activity, but not its mRNA, in renal tubules of female db/db mice (Ye et al., 2004) . Similarly, Wysocki et al. (2006) also showed reduced mRNA levels, protein levels and activity of ACE and increased ACE2 protein levels and activity but not its mRNA levels in renal tubules of female db/db mice and STZ-induced female diabetic mice. In contrast to this, Tikellis et al. (2008) demonstrated the induction of diabetes in male C57Bl6 mice decreased renal cortical expression of ACE2 mRNA and ACE2 protein, and this was associated with a significant reduction in cortical levels of Ang 1-7. In addition, Moon et al. (2008) showed increased mRNA for ACE in both tubules and glomeruli of STZ-induced male diabetic rats. ACE2 expression was increased only in tubules and decreased in glomeruli, whereas mRNA expression was unaltered in these diabetic rats. Previously, we have shown increased expression of ACE2 in kidney sections from type 2 diabetic rats (Pandey et al., 2015) . These reports clearly indicate the site-specific expression of ACE and ACE2 protein and of their mRNA, but their activities are not well correlated in diabetic kidney, and even species, strain, age, sex and the extent of glucose levels may also affect the expression of these two enzymes. However, drugs or agents that inhibit ACE activity and increase ACE2 activity or expression have proved to be effective in DN, irrespective of gender (Amann et al., 2003; Gross et al., 2003; Alderson et al., 2004; Oudit et al., 2010; Riera et al., 2016) .
In our study, DIZE treatment only reduced the plasma levels of ACE but not that in the whole kidney or glomeruli, whereas further increase was observed in both whole kidney and glomeruli when DIZE was combined with the AT 2 receptor antagonist (Figure 2A, C, D) . Urinary ACE levels were increased only in the group treated with DIZE and PD123319 and remained unaltered in other groups ( Figure 2B ). Further, ACE2 protein was increased in whole kidneys from groups treated with DIZE or DIZE with PD123319 ( Figure 2G ). On the other hand, DIZE treatment restored the decreased levels of ACE2 and, combined with PD123319, DIZE failed to restore these levels in isolated glomeruli ( Figure 2H ). In addition, DIZE treatment reduced the mRNA expression of ACE in whole kidney and increased the mRNA expression of ACE2 in glomeruli of diabetic animals, whereas adding PD123319 had no effect on these actions of DIZE ( Figure 4A, B, F, G) . Recent studies have demonstrated that the increased urinary levels of ACE2 and activity in animal models of DN were due to increased activity of ADAM17 and that inhibition of ADAM17 reduced urinary ACE2 levels and activity (Salem et al., 2014; Riera et al., 2016) . In our study, DIZE significantly reduced levels of urinary ACE2, whereas DIZE combined with PD123319 lost this effect to some extent and resulted in increased urinary ACE2 levels ( Figure 2A ). These results suggest that the protective actions of DIZE were exerted mainly through increasing renal ACE2 levels and the termination of the protective actions of DIZE by the AT 2 receptor antagonist may correlate with the increased expression of ACE in whole kidney, glomeruli and the reduced expression of ACE2 in glomeruli.
Next, we checked the activity of ACE and ACE2 indirectly through quantifying the levels of Ang II and Ang 1-7 in plasma, whole kidney and isolated glomeruli. RAS activation is critical for the development of DN (Burns, 2000) . Increased levels of Ang II is a major outcome of the activation of the RAS, through the actions of ACE (Kobori et al., 2013) . Ang II was up-regulated in plasma and renal tissue of DN (Mezzano et al., 2003) , whereas Ang 1-7 was down-regulated in plasma and renal tissue of diabetic animals (Zhang et al., 2015a) . In line with these reports, we observed increased levels of Ang II and reduced levels of Ang 1-7 in plasma, whole kidney and isolated glomeruli from diabetic animals (Figure 3 ). This can be attributed to the increased and decreased ACE and ACE2 activity in plasma, whole kidney and isolated glomeruli of diabetic animals. However, the high dose of DIZE decreased Ang II and increased Ang 1-7 in plasma, whole kidney and isolated glomeruli, and further, AT 2 receptor blockade reversed the effect of DIZE in whole kidney and isolated glomeruli, but not in plasma ( Figure 3A-F) . These results indicate that ACE2 activity in renal tissue was increased after DIZE administration, and that this increase was lost in presence of AT 2 receptor blockade, implying a role for AT 2 receptors in the activation of ACE2.
There are many reports of the protective actions of Ang 1-7, which acts through MAS1 receptors and counteracts the actions of Ang II at AT 1 receptors. Recently, Zhang et al. (2015a) demonstrated that a large dose of Ang 1-7 (800 ng·kg À1 ·min À1 ) administered s.c. by an embedded mini-osmotic pump in STZ-induced diabetic rats, for 4 weeks, significantly improved renal function, attenuated glomeruli sclerosis, reduced oxidative stress markers (NOX4 and p47phox) and decreased the expression of ECM markers (collagen IV and TGF-β1) through increasing the expression of renal MAS1 receptors, and all these effects were blocked by the MAS1 receptor antagonist (A779). In another recent study, Shi et al. (2015) demonstrated similar effects of Ang 1-7 in DN, when administered at a dose of 500 μg·kg À1 ·day À1 for 6 weeks in Akita mice, and these effects were blocked by the MAS1 receptor antagonist. However, both the studies showed down-regulation of MAS1 receptors in diabetic animals, and a large amount of Ang 1-7 was needed to restore the MAS1 receptor expression. (Shi et al., 2015; Zhang et al., 2015a) . Down-regulation of Ang 1-7 and MAS1 receptors have also been reported in human diabetic kidneys (Mizuiri et al., 2012) . In our study, we found a loss of MAS1 receptors in diabetic kidneys,but DIZE administration did not restore these levels even after increasing the Ang 1-7 levels, at both mRNA and protein levels in diabetic kidney (Figure 5E, F) . This suggests that the large doses of Ang 1-7 used by Zhang et al. (2015a) and Shi et al. (2015) may be required for the transcriptional and translational activation of MAS1 receptors. Thus, in our study, the DIZE-mediated reno-protective actions in DN were not mediated through the Ang 1-7/MAS1 pathway. However, we did observe increased mRNA and protein levels of AT 2 receptors in diabetic kidney after treatment with DIZE ( Figures 1E, I and 5C, D). Previously, Sourris et al. (2010) showed that the protective effect of RAGE blockade in a mouse model of DN is through increased expression of AT 2 receptors. Ang 1-7 is known to show its protective actions through activating AT 2 receptors, actions which were blocked by AT 2 receptor antagonists (Ohshima et al., 2014) . Therefore, our results strongly suggest that the DIZE-mediated reno-protection we have observed here is more likely to be mediated through the Ang 1-7/ AT 2 receptor-mediated pathway (Figure 8 ). Ang 1-7 and AT 2 receptors also regulate and counteract the actions of AT 1 receptor agonists (Miura et al., 2010; Ohshima et al., 2014; Galandrin et al., 2016) . Further, in our study, DIZE administration significantly decreased the levels of diabetesinduced AT 1 receptor protein, but not the mRNA . Blockade of AT 2 receptors again increased AT 1 receptor protein and mRNA levels in diabetic kidneys ( Figure 5A , B, C, H). Moreover, chronic activation of AT 2 receptors prevented caspase-3-mediated apoptosis and renal fibrosis in type 2 DN (Pandey and Gaikwad, 2017) . Interestingly, in support of these results, DIZE-mediated reno-protection was lost in presence of AT 2 receptor blockade which re-induced renal fibrosis, with an increase in fibrotic markers (TGF-β, fibronectin and collagen IV) ( Figure 6 ) and increased glomerular apoptosis, with elevated levels of cleaved PARP and cleaved caspase-3 (Figure 7 ) in glomeruli. In conclusion, the DIZE-mediated reno-protection in type 1 diabetic animals was mediated through the ACE2/Ang 1-7/ AT 2 receptor pathway (Figure 8 ), and hence, treatment with DIZE should be beneficial in human DN as well as in other abnormalities where the ACE2/Ang 1-7/ AT 2 receptor pathway is dysregulated.
Figure 8
Proposed mechanism of action of DIZE. DIZE prevented diabetes-induced renal abnormalities like decreased ACE2 activity, ACE2 expression in glomeruli and Ang 1-7 levels and increased AT 1 receptors, fibrotic and apoptotic markers by acting through ACE2/Ang 1-7/AT 2 receptor axis.
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